INTRODUCTION {#s1}
============

Osteosarcoma is the most common bone malignancy with an incidence of 4--5 cases per million people \[[@R1]\]. It usually develops in the proximal humerus, proximal tibia, and metaphyseal regions of the distal femur. The probability of osteosarcoma occurrence is two times higher in boys than in girls. With the development of multidisciplinary treatments, the five-year survival rate has significantly improved to approximately 60--70% in patients with localized tumor. However, it is difficult diagnose osteosarcoma during the early disease stages, and approximately half of all patients develop metastases. These patients with metastasis or recurrence have a low 5-year survival rate \[[@R2]\]. Therefore, new biomarkers are essential to properly assess the prognosis of osteosarcoma. The biomarkers with most potential as prognostic factors are the microRNAs (miRNAs).

miRNAs are a class of endogenously expressed small non-coding RNAs 18--25 nucleotides in length. They negatively regulate gene expression by base pairing to the 3′ untranslated region of target mRNAs. These molecules are involved in almost all biological processes. Accumulating evidence suggests that miRNAs can function as tumor suppressors or oncogenes by targeting genes involved in tumor cell differentiation, proliferation, apoptosis and metastasis. Recently, many studies have shown that numerous miRNAs are either overexpressed or underexpressed in osteosarcoma \[[@R1]\] and are often associated with the entire process of tumor development \[[@R3]\]. The relationship between miRNA expression and the prognosis of patients with osteosarcoma has been more and more reported \[[@R3]--[@R5]\]. In this study, we performed a systematic review and meta-analysis, to better understand the prognostic value of miRNAs in osteosarcoma. Using a systemic review and meta-analysis, this study comprehensively evaluated the prognostic value of miRNA expression in osteosarcoma.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A total of 1,212 references were initially retrieved using the search strategy. After screening the titles and abstracts, 63 references reported on the correlation between miRNA expression and either patient survival or disease recurrence in osteosarcoma. Among these, 35 studies reported at least one unique miRNA, so a pooled analysis would not be possible \[[@R6]--[@R40]\]. Finally, 24 articles encompassing 30 studies were include in the meta-analysis \[[@R3]--[@R5], [@R41]--[@R61]\] (Figure [1](#F1){ref-type="fig"}). The characteristics of the articles are shown in Table [1](#T1){ref-type="table"}.

![Flow diagram of the study selection process](oncotarget-08-81062-g001){#F1}

###### The main characteristics of all studies in the meta-analysis

  Study                           country   Sample number   Tumor stage I/II/III/IV   MiRNAs identified                            Follow-up months   Detected sample   Assay method   Cut-off value   Multivariate analysis   Survival analysis
  ------------------------------- --------- --------------- ------------------------- -------------------------------------------- ------------------ ----------------- -------------- --------------- ----------------------- -------------------
  Lu 2017 \[[@R3]\]               China     92              0/73/19/0                 MiR-26a                                      over 60            tissue            qRT-PCR        median          NO                      OS
  Song 2014 \[[@R4]\]             China     144             IIA62/IIB-III82           MiR-26a                                      median 83          tissue            qRT-PCR        median          NO                      OS, DFS
  Sanchez-Diaz 2014 \[[@R5]\]     USA       27              NR                        MiR-26a, miR-221, miR-126, miR-21, miR-92a   NR                 tissue            qRT-PCR        median          YES                     OS, RFS
  Hong 2014 \[[@R41]\]            China     80              I-II50/III-IV30           MiR-29a/b/c                                  over 40            serum             qRT-PCR        median          NO                      OS, DFS
  Yang 2015 \[[@R42]\]            China     108             IIA63/IIB-III45           MiR-221                                      median 26.2        serum             qRT-PCR        median          YES                     OS, RFS
  Liu 2015 \[[@R43]\]             China     35              NR                        MiR-214                                      NR                 tissue            qRT-PCR        median          NO                      OS
  Wang 2014 \[[@R45]\]            China     92              NR                        MiR-214                                      median 82          tissue            qRT-PCR        median          YES                     OS, PFS
  Allen-Rhoades 2015 \[[@R44]\]   USA       40              NR                        MiR-214                                      NR                 plasma            qRT-PCR        other           NO                      OS
  Liu 2015 \[[@R46]\]             China     122             I-II81/III-IV41           MiR-126                                      NR                 tissue            qRT-PCR        median          YES                     OS
  Han 2015 \[[@R47]\]             China     107             IIA32/IIB-III75           MiR-195                                      median 42          tissue            qRT-PCR        median          YES                     OS
  Han 2015 \[[@R47]\]             China     99              IIA27/IIB-III72           MiR-195                                      NR                 tissue            qRT-PCR        median          YES                     OS
  Cai 2015 \[[@R48]\]             China     166             IIA68/IIB-III98           MiR-195                                      median 87          serum             qRT-PCR        median          YES                     OS
  Han 2015 \[[@R49]\]             China     105             IIA46/IIB-III59           MiR-124                                      over 60            tissue            qRT-PCR        median          NO                      OS
  Wang 2016 \[[@R50]\]            China     69              6/48/15/0                 MiR-124                                      over 20            tissue            qRT-PCR        other           NO                      OS
  Xu 2014 \[[@R51]\]              China     79              I-II39/III40              MiR-9                                        NR                 tissue            qRT-PCR        median          NO                      OS
  Fei 2014 \[[@R52]\]             China     118             I-IIA64/IIB-III54         MiR-9                                        NR                 serum             qRT-PCR        other           NO                      OS
  Yuan 2012 \[[@R53]\]            China     65              19/46/0/0                 MiR-21                                       NR                 serum             qRT-PCR        median          YES                     OS
  Ren 2016 \[[@R54]\]             China     84              I-IIA36/IIB-III48         MiR-21                                       median 86          tissue            qRT-PCR        median          YES                     OS, DFS
  Xu 2014 \[[@R55]\]              China     115             NR                        MiR-382                                      over 60            tissue            qRT-PCR        median          NO                      OS
  Xu 2014 \[[@R56]\]              China     168             0/0/35/133                MiR-382                                      over 40            tissue            qRT-PCR        median          NO                      MFS
  Sarver 2013 \[[@R57]\]          USA       16              NR                        MiR-382                                      NR                 tissue            qRT-PCR        median          NO                      OS, MFS
  Ma 2014 \[[@R58]\]              China     89              I-III58/IV31              MiR-148a                                     median 41          blood             qRT-PCR        median          NO                      OS, DFS
  Zhang 2016 \[[@R59]\]           China     92              NR                        MiR-148a                                     NR                 tissue            qRT-PCR        median          NO                      OS
  Meng 2016 \[[@R60]\]            China     45              IIA27/IIB-III18           MiR-92a                                      median 36          serum             qRT-PCR        other           NO                      OS
  Wu 2010 \[[@R61]\]              China     42              2/36/4/0                  MiR-21                                       mean 54.5          tissue            qRT-PCR        median          NO                      OS

OS: overall survival; DFS: disease-specific survival; RFS: recurrence-free survival; MFS: metastasis-free survival.

Quality assessment {#s2_2}
------------------

Every eligible study enrolled in our meta-analysis was evaluated by the Newcastle-Ottawa Quality Assessment Scale (NOS). The NOS scores of every study range from 4 to 8, with an average of 6.54. The detailed information of NOS scores is shown in Table [2](#T2){ref-type="table"}.

###### Newcastle-Ottawa scale scores

  Study                           Selection   Comparability   Outcome       Total
  ------------------------------- ----------- --------------- ------------- -------
  Lu 2017 \[[@R3]\]               4           2               2 ^g^         8
  Song 2014 \[[@R4]\]             4           1 ^f^           2 ^g^         7
  Sanchez-Diaz 2014 \[[@R5]\]     4           0 ^e^ ^f^       1 ^h\ i^      5
  Hong 2014 \[[@R41]\]            4           1 ^f^           2 ^g^         7
  Yang 2015 \[[@R42]\]            4           1 ^f^           2 ^g^         7
  Liu 2015 \[[@R43]\]             4           0 ^e^ ^f^       1 ^h\ i^      5
  Wang 2014 \[[@R45]\]            4           0 ^e^ ^f^       3             7
  Allen-Rhoades 2015 \[[@R44]\]   4           0 ^e^ ^f^       1 ^h\ i^      5
  Liu 2015 \[[@R46]\]             4           0 ^e^ ^f^       0 ^g\ h\ i^   4
  Han 2015 \[[@R47]\]             4           2               2 ^h^         8
  Cai 2015 \[[@R48]\]             4           1 ^f^           3             8
  Han 2015 \[[@R49]\]             4           1 ^f^           2 ^g^         7
  Wang 2016 \[[@R50]\]            4           2               1 ^h\ i^      7
  Xu 2014 \[[@R51]\]              4           1 ^f^           1 ^h\ i^      6
  Fei 2014 \[[@R52]\]             4           2               1 ^h\ i^      7
  Yuan 2012 \[[@R53]\]            4           1 ^f^           1 ^h\ i^      6
  Ren 2016 \[[@R54]\]             4           1 ^f^           1 ^h\ i^      6
  Xu 2014 \[[@R55]\]              4           1 ^e^           2 ^g^         7
  Xu 2014 \[[@R56]\]              4           2               2 ^g^         8
  Sarver 2013 \[[@R57]\]          4           0 ^e^ ^f^       0 ^g\ h\ i^   4
  Ma 2014 \[[@R58]\]              4           2               2 ^g^         8
  Zhang 2016 \[[@R59]\]           4           0 ^e^ ^f^       0 ^g\ h\ i^   4
  Meng 2016 \[[@R60]\]            4           2               2 ^g^         8
  Wu 2010 \[[@R61]\]              4           2               2 ^g^         8

Reasons for lost stars: ^a^ no description of the derivation of the cohort; ^b^ no description of the derivation of the non-exposed cohort; ^c^ no description of exposure ascertainment; ^d^ no description of whether outcome of interest was not present at the start of study; ^e^ study not controlling the most important factor such as TNM stage; ^f^ study not controlling other additional factors, such as age, gender, and smoke; ^g^ no description of outcome assessment; ^h^ inadequacy of follow-up of cohorts; ^I^ follow-up not long enough for outcomes to occur.

miR-21 {#s2_3}
------

There were 4 studies assessing miR-21 as a predictor of survival in osteosarcoma using multivariate analysis, among which 3 used tumor tissues (*n* = 153) \[[@R5], [@R54], [@R61]\] and 1 used serum samples (*n* = 65) \[[@R53]\] (Table [3](#T3){ref-type="table"}). Once pooled, studies with different baselines showed obvious statistical heterogeneity. Hence, we pooled the HRs using a random-effects model. The results showed that upregulated miR-21 was associated with worse overall survival (OS) in osteosarcoma (HR=2.60, 95% CI 1.39--4.89, *P* = 0.003) (Figure [2](#F2){ref-type="fig"}). Considering the inter-study heterogeneity, we excluded the serum miR-21 study and pooled the remaining tissue-based miR-21 studies. The results showed that elevated levels of miR-21 in tissue was associated with worse OS in patients with osteosarcoma (HR=2.88, 95% CI 1.12--7.38, *P* = 0.028). There was only one study that evaluated the correlation between miR-21 expression and disease-specific survival (DFS) in osteosarcoma, which reported that high levels of miR-21 were associated with poor DFS in osteosarcoma. Therefore, miR-21 may act as a marker of poor prognosis in patients with osteosarcoma.

###### Summary of hazard ratios of miRNA expression in osteosarcoma

  MiRNA      No. of studies   No. of patients   Survival outcome   Effects model   HR (95% CI)          *P* value    Heterogeneity                 Reference
  ---------- ---------------- ----------------- ------------------ --------------- -------------------- ------------ ----------------------------- -----------------------------------
  MiR-21     4                218               OS                 Random          2.60 (1.39--4.89)    0.003\*      *I*^2^ = 65.0%; *P* = 0.036   \[[@R5], [@R53], [@R54], [@R61]\]
  MiR-214    3                166               OS                 Fixed           3.81 (2.13--6.83)    \< 0.001\*   *I*^2^ = 42.8%; *P* = 0.174   \[[@R43]--[@R45]\]
  MiR-382    2                171               OS                 Fixed           0.51 (0.29--0.87)    0.013\*      *I*^2^ = 16.6%; *P* = 0.274   \[[@R55], [@R57]\]
  MiR-382    2                184               MFS                Fixed           0.45 (0.30--0.67)    \< 0.001\*   *I*^2^ = 21.0%; *P* = 0.261   \[[@R56], [@R57]\]
  MiR-26a    2                236               OS                 Fixed           0.43 (0.29--0.62)    \< 0.001\*   *I*^2^ = 0.0%; *P* = 0.876    \[[@R3], [@R4]\]
  MiR-29a    2                127               OS                 Fixed           2.66 (1.53--4.63)    0.001\*      *I*^2^ = 46.0%; *P* = 0.174   \[[@R5], [@R41]\]
  MiR-221    2                135               OS                 Random          3.28 (0.76--14.28)   0.113        *I*^2^ = 85.5%; *P* = 0.009   \[[@R5], [@R42]\]
  MiR-221    2                135               RFS                Random          2.92 (0.69--12.28)   0.144        *I*^2^ = 82.3%; *P* = 0.017   \[[@R5], [@R42]\]
  MiR-126    2                149               OS                 Random          0.56 (0.34--0.94)    0.029\*      *I*^2^ = 67.0%; *P* = 0.082   \[[@R5], [@R46]\]
  MiR-195    3                372               OS                 Fixed           0.38 (0.27--0.54)    \< 0.001\*   *I*^2^ = 0.0%; *P* = 0.745    \[[@R47], [@R48]\]
  MiR-124    2                174               OS                 Fixed           0.34 (0.21--0.57)    \< 0.001\*   *I*^2^ = 0.0%; *P* = 0.810    \[[@R49], [@R50]\]
  MiR-9      2                197               OS                 Fixed           4.25 (3.10--5.84)    \< 0.001\*   *I*^2^ = 38.6%; *P* = 0.202   \[[@R51], [@R52]\]
  MiR-148a   2                181               OS                 Random          2.29 (1.26--4.16)    0.006\*      *I*^2^ = 53.3%; *P* = 0.143   \[[@R58], [@R59]\]
  MiR-92a    2                72                OS                 Random          1.84 (0.81--4.17)    0.143        *I*^2^ = 84.3%; *P* = 0.012   \[[@R5], [@R60]\]

OS: overall survival; RFS: recurrence-free survival; MFS: metastasis-free survival.

![Forest plot of the relationship between overexpression miR-21, miR-221, miR-126, miR-148a, and miR-92a and overall survival (OS) in osteosarcoma patients with random-effects model](oncotarget-08-81062-g002){#F2}

miR-214 {#s2_4}
-------

There were 3 studies that assessed miR-214 as a predictor of survival in osteosarcoma using univariate analysis (*n* = 176), of which 2 used tumor tissues \[[@R43], [@R45]\] and 1 used plasma samples \[[@R44]\] (Table [3](#T3){ref-type="table"}). Based on the 3 studies providing OS of patients, the pooled HR of 3.81 (95% CI 2.13--6.83, *P* \< 0.001) indicated that elevated miR-214 was significantly associated with poor prognosis in osteosarcoma (Figure [3](#F3){ref-type="fig"}). In the subgroups that analyzed miR-214 in tumor tissue, we found that patients with high miR-214 expression in tissue had a shorter OS (HR = 3.02, 95% CI 1.55--5.88, *P* = 0.001). In addition, Wang et al. reported that upregulation of miR-214 was significantly associated with worse PFS in osteosarcoma. Therefore, high levels of miR-214 predict a worse clinical outcome.

![Forest plot of the relationship between overexpression miR-214, miR-382, miR-26a, miR-29a, miR-195, miR-124, and miR-9 and overall survival (OS) in osteosarcoma patients with fixed-effects model](oncotarget-08-81062-g003){#F3}

miR-382 {#s2_5}
-------

Three studies showed that elevated miR-382 levels in tumor tissue were predictive of favorable OS and metastasis-free survival (MFS) in osteosarcoma as assessed using univariate analysis (*n* = 299) \[[@R55]--[@R57]\] (Table [3](#T3){ref-type="table"}). We calculated a pooled HR for the correlation between elevated miR-382 expression and OS (HR: 0.51; 95% CI 0.29--0.87, *P* = 0.013) (Figure [3](#F3){ref-type="fig"}). In addition, the combined HR for MFS was 0.45 (95% CI 0.30--0.67, *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}). The pooled HRs for OS and MFS were consistent, and we can conclude that draw a conclusion that miR-382 indicated poor prognosis in osteosarcoma.

![Forest plot of the relationship between overexpression miR-382 and metastasis-free survival (MFS) in osteosarcoma patients with fixed-effects model](oncotarget-08-81062-g004){#F4}

miR-26a {#s2_6}
-------

Two studies described low levels of miR-26a in tumor tissue as a predictive biomarker for worse OS in osteosarcoma based on univariate analyses (*n* = 236) \[[@R3], [@R4]\] (Table [3](#T3){ref-type="table"}). The combined HR showed that elevated levels of tissue-based miR-26a were significantly associated with a better OS outcome in osteosarcoma (HR: 0.43; 95% CI 0.29--0.62, *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}). Moreover, Song et al. reported that low miR-26a expression was associated with worse clinicopathological characteristics and DFS in osteosarcoma. Therefore, miR-26a may act as a tumor suppressor in osteosarcoma.

miR-29a/b/c {#s2_7}
-----------

Two studies reported that miR-29a overexpression is a poor prognostic marker in osteosarcoma based on multivariate analyses (*n* = 127) \[[@R5], [@R41]\] (Table [3](#T3){ref-type="table"}). A combined HR of 2.66 (95% CI 1.53--4.63, *P* = 0.001) showed that miR-29a overexpression was significantly associated with poor OS in osteosarcoma (Figure [3](#F3){ref-type="fig"}). In addition, Hong et al. reported that miR-29b upregulation was also significantly associated with worse OS and DFS in osteosarcoma. However, the OS and DFS of osteosarcoma patients with high levels of miR-29c expression showed no significant differences from the OS and DFS of patients with low levels of miR-29c expression.

miR-221 {#s2_8}
-------

Two studies assessed high miR-221 levels as a predictor of poor OS and recurrence-free survival (RFS) in osteosarcoma (*n* = 135) \[[@R5], [@R42]\] (Table [3](#T3){ref-type="table"}). The baselines of the patients in these 2 studies were similar. The conclusions were reached using a multivariate analysis. The combined results showed that miR-221 expression was not associated with either worse OS (HR=3.28; 95% CI 0.76--14.28, *P* = 0.113) (Figure [2](#F2){ref-type="fig"}) or RFS (HR= 2.92; 95% CI 0.69--12.28, *P* = 0.144) (Figure [5](#F5){ref-type="fig"}) in osteosarcoma. Therefore, the prognostic value of miR-221 remains unclear.

![Forest plot of the relationship between overexpression miR-221 and recurrence-free survival (RFS) in osteosarcoma patients with random-effects model](oncotarget-08-81062-g005){#F5}

miR-126 {#s2_9}
-------

Two studies reported that high miR-126 expression in tumor tissue is a favourable prognostic marker in osteosarcoma using multivariate analyses (*n* = 149) \[[@R5], [@R46]\] (Table [3](#T3){ref-type="table"}). The combined HR indicated that elevated levels of miR-126 in tumor tissue were significantly associated with longer OS in osteosarcoma (HR: 0.56; 95% CI 0.34--0.94, *P* = 0.029) (Figure [2](#F2){ref-type="fig"}).

miR-195 {#s2_10}
-------

Two articles comprising 3 studies researched the relationship between miR-195 and prognosis in osteosarcoma (*n* = 372) \[[@R47], [@R48]\] (the study by Han et al. contained two independent cohorts \[[@R47]\]) (Table [3](#T3){ref-type="table"}). A combined HR of 0.38 (95% CI 0.27--0.54, *P* = 0.001) showed that elevated miR-195 levels were significantly associated with poor OS in osteosarcoma (Figure [3](#F3){ref-type="fig"}).

miR-124 {#s2_11}
-------

Two studies reported that high miR-124 expression in tumor tissue is a favourable prognostic marker in osteosarcoma based on univariate analyses (*n* = 174) \[[@R49], [@R50]\] (Table [3](#T3){ref-type="table"}). The baselines of the patients in these 2 studies were similar. miR-124 was measured in tissue, and the pooled estimate of risk was 0.34 (95% CI 0.21--0.57 *P* \< 0.001) with no significant inter-study heterogeneity (*P* = 0.810, *I2*=0%) (Figure [3](#F3){ref-type="fig"}). Thus, miR-124 may act as a marker for increased OS in patients with osteosarcoma.

miR-9 {#s2_12}
-----

Two studies reported that elevated miR-9 levels are a predictive marker for worse OS in osteosarcoma (*n* = 197) \[[@R51], [@R52]\] (Table [3](#T3){ref-type="table"}). The combined HR showed that elevated miR-9 levels were significantly associated with worse OS outcome in osteosarcoma (HR: 4.25; 95% CI 3.10--5.84, *P* \< 0.001) (Figure [3](#F3){ref-type="fig"}).

miR-148a {#s2_13}
--------

Two studies reported that high levels of miR-148a expression are a strong prognostic marker in osteosarcoma based on univariate analyses (*n* = 181) \[[@R58], [@R59]\] (Table [3](#T3){ref-type="table"}). A combined HR of 2.29 (95% CI 1.26--4.16, *P* = 0.006) showed that miR-148a overexpression was significantly associated with poor OS in osteosarcoma (Figure [2](#F2){ref-type="fig"}). In addition, Ma et al. reported that miR-148a upregulation was also significantly associated with worse DFS in osteosarcoma. Therefore, miR-148a may play a role as an oncogene in osteosarcoma.

miR-92a {#s2_14}
-------

Two studies reported that high levels of miR-92a are a poor prognostic marker in osteosarcoma (*n* = 72) \[[@R5], [@R60]\] (Table [3](#T3){ref-type="table"}). The combined results showed that miR-92a expression was not associated with worse OS (HR=1.84; 95% CI 0.81--4.17, *P*=0.143) in osteosarcoma (Figure [2](#F2){ref-type="fig"}). Therefore, the prognostic value of miR-92a remains unclear.

Publication bias {#s2_15}
----------------

Publication bias was assessed using Egger\'s and Begg\'s tests. All the *P* values of Egger\'s and Begg\'s tests were bigger than 0.05, indicating that no significant publication bias was observed in our meta-analysis. We did not analyse the publication bias using funnel plots because of the number of included studies.

DISCUSSION {#s3}
==========

Various chemotherapy regimens have significantly improved the survival of patients with osteosarcoma. However, patients receiving similar therapy usually presented outcomes, suggesting an urgent demand for reliable prognostic biomarkers. With the development of high-throughput array profiling, it is possible to obtain a more accurate prediction of patient prognosis in osteosarcoma based on the miRNA profile. In our study, our aim was to identify miRNAs that were correlate with the survival of patients with osteosarcoma, which could be used to inform treatment decisions and evaluate patient prognosis.

Kim et al. performed a previous meta-analysis assessing the prognostic value of miRNAs in osteosarcoma \[[@R62]\]. A total of 25 studies comprising 2,278 patients were included in that analysis. They concluded that decreased miRNA expression in tumor tissue is associated with worse outcome of patients with osteosarcoma. However, in our opinion, the results of their study are not convincing enough. In Kim\'s study, different miRNAs (miR-132, 145, 382, 133a, 26a, 340, 20a, 92a, 143, 451, 144, 22, 195, 124, 449a, 99a, 224, 210, 17--92 cluster, 128, 9, 214, 542-5p, 130b, 130a, 199b-5p) were pooled together for analysis. The function and targets of each miRNA are not the same, and the expression of the different miRNAs is highly varied. It is meaningless to simply combine the different miRNAs in a single meta-analysis, and the logic of that study is faulty. In our study, we revealed that high levels of miR-21, miR-214, miR-29, miR-9 and miR-148a were associated with worse outcomes in osteosarcoma, while miR-382, miR26a, miR-126, miR-195 and miR-124 expression showed the opposite results. We did not pool these miRNAs together.

Thus, our research represents the first focused systematic review and pooled analysis of prognostic miRNAs relevant to osteosarcoma. The results of our meta-analysis revealed that high levels of miR-21, miR-214, miR-29, miR-9 and miR-148a were associated with poor prognosis in osteosarcoma. Additionally, downregulated miR-382, miR26a, miR-126, miR-195 and miR-124 expression indicated poor prognosis in osteosarcoma.

miR-21 has often been reported to play as tumor oncogene in various types of tumors. In osteosarcoma, it modulates cell invasion and migration by directly targeting RECK and PTEN \[[@R63], [@R64]\]. In addition, miR-21 reduced the anti-tumor effect of cisplatin by regulating Bcl-2 expression in osteosarcoma cells \[[@R65]\]. miR-214 can function as either an oncogene or a tumor suppressor in various types of human cancer. In osteosarcoma, miR-214 promotes cell proliferation and invasion by regulating LZTS1 expression \[[@R66]\]. Elevated miR-214 levels promotes the progression of human osteosarcoma by regulating Wnt/β-catenin signaling pathway \[[@R67]\]. Knockdown of miR-29 induces apoptosis of osteosarcoma cells by regulating TGF-β1/PUMA signalling \[[@R68]\]. Upregulated miR-9 expression can increase cell proliferation, migration, and invasion as well as decrease the apoptotic ability of the cells \[[@R69]\]. miR-9 promotes cell growth by targeting the GCIP tumor suppressor in osteosarcoma \[[@R70]\]. Overexpression of miR-148a promotes osteosarcoma cell growth by targeting PTEN \[[@R59]\]. Thus, miR-21, miR-214, miR-9 and miR-148a function as onco-miRNAs in osteosarcoma.

miR-382 overexpression restrained osteosarcoma cell proliferation and chemoresistance by regulating HIPK3 and KLF12 \[[@R55]\]. miR-382 overexpression inhibited cancer stem cell-induced tumor formation by directly targetingYB-1, and the combination of miR-382 overexpression with doxorubicin treatment prevented disease relapse in osteosarcoma patients \[[@R56]\]. miR-26a inhibits tumor growth of osteosarcoma and the stem cell-like phenotype by targeting Jagged1 \[[@R3]\]. miR-26a could also inhibit the proliferative abilities of osteosarcoma by targeting IGF-1 \[[@R71]\]. miR-126 promotes apoptosis and inhibits proliferation in osteosarcoma cells without significantly effecting cell cycle arrest at G1 phase \[[@R72]\]. miR-126 overexpression in osteosarcoma cells inhibited cell growth and invasion by targeting Sox2 \[[@R73]\]. Overexpression of miR-195 inhibits cell growth and invasion in osteosarcoma cells by targeting CCND1 \[[@R47]\]. miR-195 overexpression inhibited cell invasion and cell growth in osteosarcoma cells by targeting FASN \[[@R74]\]. Overexpression of miR-124 could reduce osteosarcoma cell proliferation, invasion and migration as well as promote cell apoptosis \[[@R49]\]. miR-124 inhibited cell growth and invasion in osteosarcoma cells by targeting ROR2, SPHK1, Rac1 and B7-H3 \[[@R50], [@R75]--[@R77]\]. Thus, miR-382, miR26a, miR-126, miR-195 and miR-124 act as tumor suppressors in osteosarcoma, which is consistent with our results; thus, our conclusions are reliable and robust.

However, our study still has some limitations. First, some of the pooled analyses for miR-21, miR-221, miR-126, and miR-148a contained studies with significant statistical heterogeneity. Second, some HRs were extracted from the reported survival curves, which will inevitably lead to small statistical errors. Third, most of the articles included in this meta-analysis were from China. Consequently, the samples used in this study were imbalance. Finally, the cutoff value used in each study was different such that a clear threshold could not be established.

In conclusion, our pooled analysis revealed that high levels of miR-21, miR-214, miR-29, miR-9 and miR-148a were associated with poor prognosis in osteosarcoma, whereas reduced miR-382, miR26a, miR-126, miR-195 and miR-124 expression showed similar results. Further prospective multicentre that are adequately designed with a larger sample size are needed to confirm the prognostic value of this panel of miRNAs in osteosarcoma and to explore more effective therapeutic stategies. In addition, further comparative analysis among the different miRNAs should be made, to identify which find which miRNA would be the most effective marker to improving patient prognosis.

MATERIALS AND METHODS {#s4}
=====================

This systemic review and meta-analysis was performed following the Observational Studies in Epidemiology (MOOSE) guidelines \[[@R78]\].

Search strategy {#s4_1}
---------------

Literature searches were conducted using the PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang data-bases (final search conducted January 1, 2017). The keywords combinations in the search strategy were "microRNA OR microRNAs OR miR OR miRNA" (all fields) AND "osteosarcomas OR osteosarcoma OR osteogenic sarcoma" (all fields) AND "prognosis OR prognostic OR survival" (all fields). Searches were limited to the English language publications.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Eligible studies included in the systemic review and meta-analysis met the following criteria: (1) focused on patients with osteosarcoma; (2) assayed type either blood or tissue samples; (3) investigated the miRNA prognostic value, (4) clearly defined the cut-off, (5) clearly described the miRNA measurement method (Table [4](#T4){ref-type="table"}). Studies were excluded if the met one of the following criteria (1) single study focused on a miRNA not investigated by another study, (2) unable to extract the data, (3) a lack of essential data for the pooled calculation.

###### Criteria for the inclusion of prognostic miRNA studies

  Study design       Prospective or retrospective cohort design with an appropriate study population
  ------------------ ---------------------------------------------------------------------------------
  Tumor type         Osteosarcoma
  Assay type         Tissue or blood
  MiRNA measure      Quantitative real time reverse transcription PCR
  Survival measure   OS or RFS or DFS or MFS
  Analysis           Reporting of the HRs including 95% CIs or Kaplan Meier survival curves
  Follow-up time     Any
  Language           English or Chinese

OS: overall survival; DFS: disease-specific survival; RFS: recurrence-free survival; MFS: metastasis-free survival.

Data extraction and quality assessment {#s4_3}
--------------------------------------

The database search was independently reviewed by two authors (D. Cheng and X. Qiu). The essential information was independently by two investigators. If the statistical variables were not described in the study, we calculated from the available numerical data in the articles using the methods described by Tierney \[[@R79]\]. The quality of included studies was assessed by NOS according to the following categories: selection (description of the derivation of the cohort, description of the derivation of the non-exposed cohort, description of exposure ascertainment, description of whether outcome of interest was not present at the start of study), comparability (study controlled the most important factor, study controlled other additional factors), and outcome of interest (description of outcome assessment, adequacy of follow-up of cohorts, follow-up long enough for outcomes to occur) \[[@R80]\]. A total of nine items were extracted and each item scored 1. The total score of NOS ranged from 0 to 9, and we considered studies as high quality if they met at least six scores.

Statistical analysis {#s4_4}
--------------------

An observed HR \< 1 suggested a more favourable prognosis in patients with miRNA overexpression, and an HR \> 1 indicated a worse prognosis. HRs and their 95% CIs were combined to measure the effective value of miRNA expression on prognosis. If the statistical data were described in the study, we extracted them directly. Otherwise, they were calculated from available numerical data in the articles according to the methods described by Tierney \[[@R79]\]. The data from Kaplan-Meier survival curves were read by Engauge Digitizer version 4.1, and three independent researchers read the curves to reduce reading variability. We also sent e-mail to the corresponding authors of eligible articles requesting additional information and original data needed for the meta-analysis. Statistical heterogeneity was assessed by calculating the *I*^2^ statistic, and assessing the *P* value \[[@R81], [@R82]\]. An *I*^2^ value exceeding 50% and/or the *P* value less than 0.05 indicated the presence of heterogeneity, and a random-effects model was used. Otherwise, the fixed-effects model was used. Publication bias was estimated using Begg\'s and Egger\'s tests. All analyses were performed using STATA vision 12.0 (Stata Corporation, College Station, TX, USA). A *P* value less than 0.05 was considered statistically significant except where otherwise specified.

**CONFLICTS OF INTEREST**

The authors disclose no potential conflicts of interest.
